Adial Pharmaceuticals, Inc.
ADILAdial Pharmaceuticals, Inc. in brief
Adial Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Encino, California, USA. Its market value was $69 M on 30 October 2026, which makes it the 20,152nd largest listed company in the world and the 3,720th largest in the USA on this site. Matt Davidson is its chief executive. Its shares trade under the symbol ADIL (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Adial Pharmaceuticals, Inc.
We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Our investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. AD04 was investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment of AUD in subjects with certain target genotypes, which were identified using our companion diagnostic genetic test. Based on our analysis of the subgroup data from the ONWARD trial, we are now focused on completing the clinical development program for AD04 in the specified genetic subgroups to meet regulatory requirements primarily in the US and secondarily in Europe/UK.
From the company's annual report filed with the US SEC: read the report
Adial Pharmaceuticals, Inc. timeline
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- ✎Renamed Adial Pharmaceuticals, Inc.Formerly ADial Pharmaceuticals, L.L.C..
- 2018
- 🔔Initial public offering as Adial Pharmaceuticals, Inc.Final prospectus filed with the SEC on 30 July 2018; shares registered for exchange trading on 23 July 2018.
- 2026
- ✎Renamed Azora Therapeutics, Inc. (DE)Formerly Adial Pharmaceuticals, Inc..
Events of Adial Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,413 (Jan 2020) · #4,352 (Jan 2021) · #4,863 (Jan 2022) · #5,721 (Dec 2022) · #5,498 (Jul 2023) · #4,726 (Jan 2024) · #2,486 (Mar 2026) · #4,048 (Aug 2026) · #3,866 (Oct 2026) · #3,724 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 13.0×
- Free cash flow yield
- -17.5%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -241.1%
- Liabilities / assets
- 21.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2022 | — | — | $-11M | $-13M | — |
| Dec 2021 | — | — | $-19M | $-19M | — |
| Dec 2020 | — | — | $-11M | $-11M | — |
| Dec 2019 | — | — | $-8M | $-9M | — |
| Dec 2018 | — | — | $-7M | $-12M | — |
| Dec 2017 | — | — | $-1M | $-1M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2022 | $-11M | — | — | $-12.71 | — |
| Dec 2021 | $-12M | $0M | $-12M | $-1.04 | — |
| Dec 2020 | $-8M | — | — | $-0.87 | — |
| Dec 2019 | $-6M | — | — | $-0.87 | — |
| Dec 2018 | $-3M | — | — | $-2.44 | — |
| Dec 2017 | $-0M | — | — | $-0.35 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-65M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportDirectors or officers changed · Other events
- Oct 28, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Shareholder vote · Regulation FD disclosure
- Oct 21, 202610-Q/AQuarterly report (amended) · period to Jun 2026
- Oct 16, 20268-KCurrent reportOther events
- Oct 2, 20268-KCurrent reportOther events
- Sep 18, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Sep 16, 20268-KCurrent reportMaterial agreement · Other events
- Aug 25, 20268-KCurrent reportUnregistered share sale
- Aug 24, 2026DEF 14AProxy statement
- Aug 21, 20268-KCurrent reportListing notice
Official filings of Adial Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-11 M
- Net income
- $-13 M
For year ending December-2022 · source: SEC filing
Balance sheet
- Total assets
- $7 M
- Total liabilities
- $1 M
- Total equity
- $5 M
As of December-2025
Top 22 institutional investors in Adial Pharmaceuticals, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | KVP Capital Advisors, LP | 210,256 | New | 1.47% | $1 M | Nov 16, 2026 |
| 2 | Diadema Partners LP | 181,890 | New | 1.27% | $1 M | Nov 16, 2026 |
| 3 | Acuta Capital Partners, LLC | 129,982 | New | 0.91% | $1 M | Nov 16, 2026 |
| 4 | Jane Street Group, LLC | 53,952 | +21,833 (+67.98%) | 0.38% | $0 M | Nov 12, 2026 |
| 5 | Citadel Advisors LLC | 29,753 | +206 (+0.70%) | 0.21% | $0 M | Nov 16, 2026 |
| 6 | XTX Topco Ltd | 26,771 | New | 0.19% | $0 M | Nov 16, 2026 |
| 7 | Geode Capital Management, LLC | 21,546 | +9,153 (+73.86%) | 0.15% | $0 M | Nov 6, 2026 |
| 8 | Vanguard Fiduciary Trust Co | 15,879 | +10,000 (+170.10%) | 0.11% | $0 M | Nov 13, 2026 |
| 9 | China Universal Asset Management Co., Ltd. | 12,800 | +4,800 (+60.00%) | 0.09% | $0 M | Oct 28, 2026 |
| 10 | Vanguard Capital Management LLC | 10,407 | +4,576 (+78.48%) | 0.07% | $0 M | Nov 13, 2026 |
| 11 | Manchester Capital Management LLC | 1,923 | 0 (0.00%) | 0.01% | $0 M | Oct 22, 2026 |
| 12 | Tower Research Capital LLC (TRC) | 1,777 | +358 (+25.23%) | 0.01% | $0 M | Nov 16, 2026 |
| 13 | UBS Group AG | 1,688 | -17,459 (-91.18%) | 0.01% | $0 M | Nov 10, 2026 |
| 14 | Barclays PLC | 1,094 | New | 0.01% | $0 M | Nov 6, 2026 |
| 15 | BlackRock, Inc. | 304 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 16 | Raffa Wealth Management, LLC | 83 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 17 | Morgan Stanley | 50 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 18 | SBI Securities Co., Ltd. | 45 | -2 (-4.26%) | 0.00% | $0 M | Oct 22, 2026 |
| 19 | Northwestern Mutual Wealth Management Co | 30 | New | 0.00% | $0 M | Nov 13, 2026 |
| 20 | Caitong International Asset Management Co., Ltd | 9 | New | 0.00% | $0 M | Oct 29, 2026 |
| 21 | Wells Fargo & Company/mn | 6 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 22 | Abound Wealth Management | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 26, 2026 |
Mutual funds holding Adial Pharmaceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 23,596 | $0 M | 0.17% | <0.01% | +347% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 361 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 310 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Adial Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Julie SaikiChief Strategy Officer | Conversion | +626,252 | — | — | 761,636 | Form 4 |
| filed | Matt DavidsonPresident and CEO, Director | Conversion | +524,954 | — | — | 819,018 | Form 4 |
| filed | Matt DavidsonPresident and CEO, Director | Conversionindirect | +101,298 | — | — | 104,725 | Form 4 |
| filed | Matt DavidsonPresident and CEO, Director | Grant or award | +232,417 | — | — | 294,064 | Form 4 |
| filed | Coastlands Capital LP10% owner | Buyindirect | +1,233 | $2.750 | $3 K | 388,308 | Form 4 |
| filed | Coastlands Capital LP10% owner | Buyindirect | +2,000 | $2.650 | $5 K | 387,075 | Form 4 |
| filed | Coastlands Capital LP10% owner | Buyindirect | +1,700 | $2.700 | $5 K | 385,075 | Form 4 |
| filed | Coastlands Capital LP10% owner | Buyindirect | +10,053 | $2.790 | $28 K | 383,375 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Adial Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2023 | Q4 2023 | $0M |
Trading halts
- 2026-11-02 14:40 UTC, code LUDP, resumed 14:45 UTC
- 2026-11-02 14:31 UTC, code LUDP, resumed 14:36 UTC
- 2026-06-11 16:43 UTC, code LUDP, resumed 16:48 UTC
- 2026-06-11 15:44 UTC, code LUDP, resumed 16:26 UTC
- 2026-02-06 00:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 8,170 shares at $4.81
- : 25,052 shares at $0.01
- : 192 shares at $3.92
- : 986 shares at $4.11
- : 485 shares at $3.51
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Adial Pharmaceuticals, Inc. scorecard#
Passes 1 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median13.0×Price to book 13.0× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-17.5%Free cash flow is -17.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-11.93 vs -68.01Diluted EPS -11.93 in fiscal 2025 against -68.01 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitabilitynot known
- –Profitable in the newest yearNo net income on file.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities4.4×Current ratio 4.41 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year244.8%Diluted shares up 244.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Adial Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Research and development | 2,620−18.9%— | 3,229+155%— | 1,267−35.0%— | 1,950r4,177−76.8%— | 8,396+43.4%— | 5,853+47.6%— | 3,966+976%— | 368+102%— | 182—— | |
| General and administrative | 5,180+2.5%— | 5,055−10.1%— | 5,621−36.9%— | 8,909r9,140−4.7%— | 9,345+84.1%— | 5,075+18.6%— | 4,279−35.3%— | 6,619+714%— | 813—— | |
| Operating expenses | 7,799−5.9%— | 8,284+20.3%— | 6,888−36.6%— | 10,859r13,317−43.7%— | 19,289+76.5%— | 10,928+32.5%— | 8,245+18.0%— | 6,987+602%— | 995—— | |
| Total costs and expenses | — | — | — | 550—— | — | — | — | — | — | |
| Operating income | −7,799—— | −8,284—— | −6,888—— | −10,859r−13,317—— | −19,289—— | −10,928—— | −8,245—— | −6,987—— | −995—— | |
| Interest and finance income | 150−16.3%— | 179+156%— | 70+10.2%— | 63r63+869%— | 6.5−79.9%— | 32−65.9%— | 95+1188%— | 7.4+1914%— | 0.4—— | |
| Share of profit of associates | −492—— | −552—— | −194—— | — | — | — | — | — | — | |
| Other non-operating income (expense) | −178—— | −4,913—— | −114−280%— | 63r585—— | −229−753%— | 35—— | −347—— | −4,644—— | −144—— | |
| Income before tax | −7,977—— | −13,197—— | −7,002—— | −10,796r−12,732—— | −19,517—— | −10,893—— | −8,591—— | −11,631—— | −1,139—— | |
| Income tax | — | — | — | −0.5—— | −94—— | — | — | — | — | |
| Income from continuing operations | — | −13,197—— | −7,002—— | −10,796—— | — | — | — | — | — | |
| Income from discontinued operations | — | — | 1,879—— | −1,935—— | — | — | — | — | — | |
| Net income including minority interests | — | — | — | — | −19,423—— | −10,893—— | −8,591—— | — | — | |
| Net income attributable to shareholders | −7,977—— | −13,197—— | −5,123—— | −12,731—— | −19,423—— | −10,893—— | −8,591—— | −11,631—— | −1,139—— | |
| Earnings per share, basic | -11.93—— | -68.01r-2.72—— | -3.60—— | -12.71r-0.51—— | -1.04—— | -0.87—— | -0.87—— | -2.44—— | -0.35—— | |
| Earnings per share, diluted | -11.93—— | -68.01r-2.72—— | -3.60—— | -12.71r-0.51—— | -1.04—— | -0.87—— | -0.87—— | -2.44—— | -0.35—— | |
| Shares, weighted average (basic) | 0.7+245%— | 0.2—— | — | 25+34.7%— | 19—— | — | — | — | — | |
| Shares, weighted average (diluted) | 0.7+245%— | 0.2r4.9−86.4%— | 1.4+42.3%— | 1.0r25−94.6%— | 19+49.1%— | 12+26.5%— | 9.9+3951%— | 0.2+39.5%— | 0.2—— | |
| Balance sheet | ||||||||||
| Cash and cash equivalents | 5,881+56.8%88.1% | 3,751+32.7%74.4% | 2,827−29.4%59.7% | 4,002−34.0%69.8% | 6,062+37.7%81.1% | 4,401−35.1%80.1% | 6,777+75.2%88.2% | 3,869+21103%82.3% | 18—52.8% | |
| Other current assets | 300r300−2.7%4.5% | 308−17.1%6.1% | 372+6.3%7.8% | 349−10.3%6.1% | 390−22.4%5.2% | 502+39.6%9.1% | 359+13.2%4.7% | 318+3428%6.8% | 9.0—26.1% | |
| Current assets | 6,181r6,181+52.3%92.6% | 4,059+26.9%80.5% | 3,199−33.1%67.5% | 4,780−26.0%83.4% | 6,462+25.8%86.4% | 5,136−33.1%93.5% | 7,673+63.5%99.9% | 4,693+17122%99.9% | 27—78.9% | |
| Property, plant and equipment | — | — | — | 50−13.3%0.9% | 58—0.8% | — | — | — | — | |
| Right-of-use (leased) assets | — | — | — | 194−21.2%3.4% | 246—3.3% | — | — | — | — | |
| Goodwill | — | — | — | 2490.0%4.3% | 249—3.3% | — | — | — | — | |
| Other intangible assets | 3.0r2.8−10.4%0.0% | 3.3−14.4%0.1% | 3.9−12.6%0.1% | 4.5−11.2%0.1% | 5.0−10.1%0.1% | 5.6−9.1%0.1% | 6.2−8.4%0.1% | 6.7−7.7%0.1% | 7.3—21.1% | |
| Investments in associates | 490r490−50.1%7.3% | 982−36.0%19.5% | 1,534—32.4% | — | — | — | — | — | — | |
| Total assets | 6,674r6,673+32.3%100% | 5,044+6.5%100% | 4,737−17.4%100% | 5,733−23.3%100% | 7,475+36.1%100% | 5,491−28.5%100% | 7,680+63.4%100% | 4,699+13503%100% | 35—100% | |
| Accounts payable | 655r655+162%9.8% | 250+142%5.0% | 103−62.6%2.2% | 276r394−3.4%4.8% | 286−55.9%3.8% | 649+241%11.8% | 190+90.8%2.5% | 100r258−70.9%2.1% | 342—990% | |
| Current liabilities | 1,397r1,397+43.2%20.9% | 976+49.4%19.3% | 653−63.5%13.8% | 1,791−34.2%31.2% | 2,722+80.8%36.4% | 1,505+179%27.4% | 539+109%7.0% | 258−75.0%5.5% | 1,032—2988% | |
| Lease liabilities (non-current) | — | — | — | 151−27.4%2.6% | 207—2.8% | — | — | — | — | |
| Total liabilities | 1,397r1,397+43.2%20.9% | 976+49.4%19.3% | 653−73.4%13.8% | 2,456−38.1%42.8% | 3,967+164%53.1% | 1,505—27.4% | — | — | — | |
| Retained earnings | −89,972r−89,972—−1348% | −81,995—−1626% | −68,798—−1452% | −63,675—−1111% | −50,943—−682% | −31,520—−574% | −20,627—−269% | −12,035—−256% | −404—−1169% | |
| Shareholders' equity | 5,277r5,276+29.7%79.1% | 4,068r4,068−0.4%80.7% | 4,084+24.6%86.2% | 3,276−6.6%57.2% | 3,508−12.0%46.9% | 3,986−44.2%72.6% | 7,141+60.8%93.0% | 4,441—94.5% | −998—−2888% | |
| Total liabilities and equity | 6,674r6,673+32.3%100% | 5,044+6.5%100% | 4,737−17.4%100% | 5,733−23.3%100% | 7,475+36.1%100% | 5,491−28.5%100% | 7,680+63.4%100% | 4,699+13503%100% | 35—100% | |
| Shares outstanding | 1.1+329%— | 0.3r6.5−84.4%— | 1.7+55.8%— | 1.1r27−94.9%— | 21+45.5%— | 14+38.8%— | 10+51.1%— | 6.9+110%— | 3.3—— | |
| Cash-flow statement | ||||||||||
| Share-based compensation | 676−15.1%— | 797−54.4%— | 1,746−48.2%— | 3,374−20.4%— | 4,240+111%— | 2,014+25.7%— | 1,602−70.2%— | 5,368+2514%— | 205—— | |
| Cash from operating activities | −6,493—— | −6,922—— | −6,807—— | −11,186—— | −11,949—— | −7,633—— | −6,339—— | −2,498—— | −495—— | |
| Capital expenditure | — | — | — | — | −65—— | — | — | — | — | |
| Acquisitions, net of cash acquired | — | — | — | — | −31—— | — | — | — | — | |
| Cash from investing activities | 150—— | — | 1,500—— | — | −34—— | −350—— | — | — | 35—— | |
| Shares issued | 3,659−9.0%— | 4,021+436%— | 750−91.8%— | 9,124−22.4%— | 11,750+128%— | 5,157—— | — | — | — | |
| Shares bought back | — | — | −1.7—— | — | — | — | — | — | — | |
| Cash from financing activities | 8,473+8.0%— | 7,846+89.9%— | 4,132−54.7%— | 9,126−33.1%— | 13,645+143%— | 5,607−39.4%— | 9,247+45.6%— | 6,349+1528%— | 390—— | |
| Change in cash | — | — | — | — | — | −2,376−182%— | 2,908−24.5%— | 3,851—— | −70—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 3.3+19.6%— | 1.8+241%— | 0.4−39.9%— | 0.4−42.1%— | 0.6r0.6*−15.2%— | 0.5r0.5−49.5%— | 0.7r0.7−27.7%— | 0.7—— | 0.7*+176%— | 1.0+398%— | 1.0—— | 0.3*—— | 0.2—— | |
| General and administrative | 14+173%— | 5.8+363%— | 5.4+370%— | 1.6+3.2%— | 1.3r1.3*+4.6%— | 1.2r1.2+5.4%— | 1.2r1.2−9.8%— | 1.5—— | 1.2*−20.4%— | 1.2+2.5%— | 1.3—— | 1.5*—— | 1.2—— | |
| Operating expenses | 63+708%— | 7.5+327%— | 52+2664%— | 2.0−11.7%— | 1.9r1.9*−2.8%— | 1.8r1.8−20.2%— | 1.9r1.9−17.7%— | 2.3—— | 1.9*+8.8%— | 2.2+62.9%— | 2.3—— | 1.8*—— | 1.4—— | |
| Operating income | −63—— | −7.5—— | −52—— | −2.0—— | −1.9r−1.9*—— | −1.8r−1.8—— | −1.9r−1.9—— | −2.3—— | −1.9*—— | −2.2—— | −2.3—— | −1.8*—— | −1.4—— | |
| Interest and finance income | 0.3+97.2%— | 0.2+254%— | 0.1+142%— | 0.0+33.1%— | 0.0r0.0*−20.8%— | 0.0r0.0−5.3%— | 0.0r0.0−53.3%— | 0.0—— | 0.1*+379%— | 0.1+395%— | 0.1—— | 0.0*—— | 0.0—— | |
| Share of profit of associates | −0.5—— | −0.1—— | −0.2—— | −0.1—— | −0.2r−0.2*—— | −0.1r−0.1—— | −0.1r−0.1—— | −0.2—— | −0.1*—— | −0.0—— | −0.2—— | — | — | |
| Other non-operating income (expense) | −57—— | −57—— | 0.0—— | −0.0−154%— | −0.1r−0.1*—— | −0.0r−0.0−253%— | −0.1r−0.1—— | 0.0—— | −0.1*—— | 0.0+92.2%— | −0.2—— | −0.1*—— | 0.0—— | |
| Income before tax | — | — | — | — | — | — | — | — | −2.1*—— | −2.2—— | −2.5—— | −1.9*—— | −1.3—— | |
| Income from continuing operations | — | — | — | — | — | — | −2.0*—— | −2.2—— | −2.1*—— | −2.2—— | — | −1.9*—— | −1.3—— | |
| Income from discontinued operations | — | — | — | — | — | — | — | — | — | — | — | −0.0*—— | −0.0—— | |
| Net income attributable to shareholders | −121—— | −65—— | −52—— | −2.0r−2.0—— | −2.0r−2.0*—— | −1.8r−1.8—— | −2.0r−2.0—— | −2.2r−2.2—— | −2.1*—— | −2.2—— | −2.5—— | −1.9*—— | −1.4—— | |
| Earnings per share, basic | — | -4.52—— | -11.25—— | -1.48—— | — | -2.02r-0.08—— | -4.61r-0.18—— | -8.52r-0.34—— | — | -0.38—— | -0.59—— | — | -1.18—— | |
| Earnings per share, diluted | — | -4.52—— | -11.25—— | -1.48—— | — | -2.02r-0.08—— | -4.61r-0.18—— | -8.52r-0.34—— | — | -0.38—— | -0.59—— | — | -1.18—— | |
| Shares, weighted average (basic) | 14+1512%— | 14+1512%— | 4.6+988%— | 1.4+424%— | — | 0.9r22−84.8%— | 0.4—— | 0.3—— | — | 5.8—— | — | — | — | |
| Shares, weighted average (diluted) | 14+1512%— | 14+1512%— | 4.6+988%— | 1.4+424%— | — | 0.9r22−84.8%— | 0.4r11−89.8%— | 0.3r6.5—— | — | 5.8+395%— | 4.2—— | — | 1.2—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 22—97.7% | 22+378%97.7% | 29+385%98.7% | 4.6+93.8%87.7% | 5.9+56.8%88.1% | 4.6−11.5%81.4% | 5.9+79.9%87.0% | 2.4—68.6% | 3.8+32.7%74.4% | 5.2+1548%77.5% | 3.3—66.4% | 2.8—59.7% | 0.3—11.0% | |
| Other current assets | 0.3—1.5% | 0.3−18.3%1.5% | 0.1−18.7%0.5% | 0.2−16.9%4.2% | 0.3r0.3−2.7%4.5% | 0.4−0.6%7.2% | 0.2−13.2%2.4% | 0.3—7.6% | 0.3−17.1%6.1% | 0.4−12.7%6.1% | 0.2—3.8% | 0.4—7.8% | 0.5—16.4% | |
| Current assets | 22—99.3% | 22+346%99.3% | 29+375%99.2% | 4.8+82.7%91.9% | 6.2r6.2+52.3%92.6% | 5.0−10.8%88.6% | 6.1+59.0%89.4% | 2.6—76.2% | 4.1+26.9%80.5% | 5.6+395%83.7% | 3.8—77.3% | 3.2—67.5% | 1.1—39.6% | |
| Other intangible assets | 0.0—0.0% | 0.0+2.6%0.0% | 0.0−2.2%0.0% | 0.0−17.6%0.1% | 0.0r0.0−10.4%0.0% | 0.0−16.2%0.1% | 0.0−15.6%0.0% | 0.0—0.1% | 0.0−14.4%0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | — | |
| Investments in associates | 0.1—0.7% | 0.1−77.0%0.7% | 0.2−66.5%0.8% | 0.4−48.5%8.1% | 0.5r0.5−50.1%7.3% | 0.6−41.0%11.4% | 0.7−35.8%10.6% | 0.8—23.7% | 1.0−36.0%19.5% | 1.1−36.9%16.2% | 1.1—22.7% | 1.5—32.4% | 1.7—60.3% | |
| Total assets | 23—100% | 23+298%100% | 29+328%100% | 5.2+51.5%100% | 6.7r6.7+32.3%100% | 5.7−15.7%100% | 6.8+37.4%100% | 3.5—100% | 5.0+6.5%100% | 6.7+134%100% | 4.9—100% | 4.7—100% | 2.9—100% | |
| Accounts payable | 1.4—6.2% | 1.4+150%6.2% | 2.6+291%9.0% | 0.6+7.7%11.0% | 0.7r0.7+162%9.8% | 0.6+74.9%9.8% | 0.7+112%9.9% | 0.5—15.4% | 0.3+142%5.0% | 0.3+288%4.7% | 0.3—6.4% | 0.1—2.2% | 0.1—2.9% | |
| Current liabilities | 5.1—22.4% | 5.1+338%22.4% | 5.1+323%17.6% | 1.5+14.0%28.9% | 1.4r1.4+43.2%20.9% | 1.2+39.3%20.4% | 1.2+80.2%17.8% | 1.3—38.4% | 1.0+49.4%19.3% | 0.8+57.0%12.4% | 0.7—13.6% | 0.7—13.8% | 0.5—18.4% | |
| Total liabilities | 5.1—22.4% | 5.1+338%22.4% | 29+2289%99.5% | 1.5+14.0%28.9% | 1.4r1.4+43.2%20.9% | 1.2+39.3%20.4% | 1.2+80.2%17.8% | 1.3—38.4% | 1.0+49.4%19.3% | 0.8+57.0%12.4% | 0.7—13.6% | 0.7—13.8% | 0.5—18.4% | |
| Retained earnings | −209—−926% | −209—−926% | −144—−495% | −92—−1760% | −90r−90—−1348% | −88—−1554% | −86—−1267% | −84—−2440% | −82—−1626% | −80—−1191% | −78—−1571% | −69—−1452% | −67—−2332% | |
| Shareholders' equity | −21—−93.5% | −21−568%−93.5% | −38−787%−132% | 3.7r3.7+74.8%71.1% | 5.3r5.3+29.7%79.1% | 4.5r4.5−23.4%79.6% | 5.6r5.6+30.7%82.2% | 2.1r2.1—61.6% | 4.1r4.1−0.4%80.7% | 5.9+152%87.6% | 4.3—86.4% | 4.1—86.2% | 2.3—81.6% | |
| Total liabilities and equity | 23—100% | 23+298%100% | 29+328%100% | 5.2+51.5%100% | 6.7r6.7+32.3%100% | 5.7−15.7%100% | 6.8+37.4%100% | 3.5—100% | 5.0+6.5%100% | 6.7+134%100% | 4.9—100% | 4.7—100% | 2.9—100% | |
| Shares outstanding | 2.6—— | 2.6−89.0%— | 2.6−87.8%— | 1.5−77.3%— | 1.1+329%— | 24+272%— | 22+402%— | 6.6—— | 0.3r6.5−84.4%— | 6.4+426%— | 4.3—— | 1.7—— | 1.2—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 1.4+105%— | 1.0+552%— | 0.1+10.5%— | 0.1−37.5%— | 0.2r0.2*−6.7%— | 0.1r0.1−21.9%— | 0.1r0.1−38.7%— | 0.2—— | 0.2*−35.8%— | 0.2−29.9%— | 0.2—— | 0.3*—— | 0.3—— | |
| Cash from operating activities | −16—— | −6.6*—— | −6.4*—— | −1.6—— | −1.3r−1.3*—— | −1.8r−1.8*—— | −1.7r−1.7*—— | −1.6—— | −1.5*—— | −1.7*—— | — | −1.2*—— | −1.4*—— | |
| Cash from investing activities | — | 0*—— | — | — | 0*—— | 0*—— | 0*—— | 0.2—— | — | — | — | 0.4*—— | 0.4*—— | |
| Shares issued | 1.2−66.2%— | 0*−100%— | 0.8*−72.4%— | 0.3+523%— | 0.1r0.1*—— | 0.5r0.5*−86.8%— | 3.1r3.1*—— | 0.1—— | 0*—— | 3.6*+2473%— | — | 0*—— | 0.1*—— | |
| Shares bought back | — | — | — | — | — | — | — | — | — | — | — | 0*—— | — | |
| Cash from financing activities | 28+378%— | −0.0*−107%— | 25*+376%— | 0.3+523%— | 2.6r2.6*—— | 0.5r0.5*−85.5%— | 5.3r5.3*—— | 0.1—— | 0*−100%— | 3.6*+2504%— | — | 3.4*—— | 0.1*—— | |
| Report | Worked out | 10-Q | 10-Q/A | 10-Q | 10-Q | 10-Q | 10-Q/A | 10-Q | 10-K | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Adial Pharmaceuticals, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Cary Claiborne | $891 K | $600 K | $464 K | $4 |
| 2024Matt Davidson | $976 K | $824 K | $352 K | $19 |
| 2023Matt Davidson | $802 K | $576 K | $412 K | $35 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Adial Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Acquisition or sale completed 1 · Directors and officers 8 · Material agreement 5 · Agreement ended 1 · New debt 1 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 4 · Shareholder vote 3 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Unregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completedDirectors and officersMaterial agreementNew debtUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2025 | $4 M | Private placement after listing | $2 to $10 million | 1 | options | SEC |
| May 2025 | $5 M | Private placement after listing | $2 to $10 million | 1 | options | SEC |
| Oct 2023 | $4 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Feb 2022 | $10 M | Private placement after listing | $10 to $50 million | 1 | options | SEC |
| Jun 2020 | $5 M | Private placement after listing | $2 to $10 million | 6 | equity, options | SEC |
| Jun 2013 | $3 M | No. 2 | $2 to $10 million | 35 | equity | SEC |
| Mar 2011 | $4 M | No. 1 | $2 to $10 million | — | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Adial Pharmaceuticals, Inc.#
$40 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues4 reports
Lobbying firms hired in 2025
RK STRATEGIES, INC. $40 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $20 K | — | 2 |
| 2025 | $40 K | — | 4 |
| 2024 | $10 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Adial Pharmaceuticals, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Adial Pharmaceuticals, Inc. compares in Biotechnology
- Market cap$69 M · higher than 30% of 726
- Price / book13.0× · lower than 12% of 534
- FCF yield-17.5% · higher than 46% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Adial Pharmaceuticals, Inc.🇺🇸 | $69 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2022
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Adial Pharmaceuticals, Inc.? Verify and update this profile — free
Show Adial Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.